Drug targeting to the kidney : N-acetyl-L-y-glutamyl derivatives as kidney-selective prodrugs by Drieman, J.C.
  
 
Drug targeting to the kidney : N-acetyl-L-y-glutamyl
derivatives as kidney-selective prodrugs
Citation for published version (APA):
Drieman, J. C. (1989). Drug targeting to the kidney : N-acetyl-L-y-glutamyl derivatives as kidney-selective
prodrugs. Maastricht: Datawyse.
Document status and date:
Published: 01/01/1989
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
The goall of drug tW%eting is to achieve high levels of dmg in the target tissue 
and low levels in other tissues. In this way a maximal pharmacologic effect can h 
produced with a minimum of side affects, i.e. the therapeutic imdex is optimized. In 
the introduction (chapter 11, a survey is given of the different stratelfies used for 
dmg targeting. The experimental section of this thesis focuses upon prodrugs as a 
dmg deliveq system to achieve a site-specific effect; in particular the mechanism 
of the renal selectivity of W-acetyl-LT-glutamyl prodrugs was imestigated. 
Part one of the experimental seaion describes studies into the renal selectivity 
of the vasodilator prodrug CGP 22979. It was s h o w  (chapter 2) that upon prodrug 
administration the active drug (CGP 18137) accumulates in renal tissue compared 
to other tissues. The half-life of the active drug appeared to be very short, due to a 
chemical reaction with ketones or aldehydes that are present in the blood. Bemuse 
of this short half-life, the active drug can only interact with the resistance vessels 
near the site where the active drug is liberated from the prodmg. This is am 
important factor in the renal selectivity of CCiP 2979,  
Studies on the possible involvement of active transport of the prodrvg in the 
renal accumulation of the active drug and the possibility of intracellular conversion 
are described in chapter 3. It was found that the enzyme x-glrcrtamyll transpeptidase 
is not involved in the renal accurnrulation of the active drug. Inhibitors of the 
transport of y-glutmy1 compounds and of other anions, on the other hand, sharply 
decreased renal active drug levels. Furthermore, it appeared that qosol ic  systems 
we able to convert the pradmg in contrast to microsomail systems. 
In order to comelate the renal levels of active drug to the phamacologic effects, 
the consequences of enzyme and transport i~llhibi.tors on the rend hernodynamic 
responses to CGP 22979 were investigated (chapter 4). The results of this study 
confirm the importance of active transport in the renal selectivity of the prodrug. 
Inhibition of r-glvtamyl transpepidase, however, caused a significant decrease in 
effect, while no attenuation of the tissue levels d active drug was found. This shows 
h a t  the levels of active dmg do not always correlate well with the pharrnstcolo$ic 
responses when the concentration measurement and the interaction of the active 
drug with its target are not at the same site. As conclwsion of part 1, a model is 
proposed for the renal handling of the prodrug. 
In part2 (chapter 5-73, experiments are described which were carried out in order 
to validate and extend this model, especially with respect to the active transport of 
the prodrug and the nature of the intracellular conversion. For this purpose, a 
prodrug was chosen of which not only the active drug, but also the prodrug itself 
and the deaceylated prodmg could be analysed, namely N-aceblr-glutamyl sol- 
fmethoxazole (chgter 5). In In vitro studies it was found that the prodrug is 
acrivated in two steps, the first one being deace~lation, fallowed by removal of the 
r-@plutamyl group. In Gvc~; it was found that the prodmg accumulated in the kidney, 
and that this accumulation w a  due to arrier-mediatd transport, sensitive to 
buthionhe swlfoximine and probenedd (see also chapter 7). 
A disadvantage of the sulfa-prodmg is that no pharmacologic eEea  can be 
meawred. Hence, a prodrug was wanted with an inuacellular site af adon  (as 
opposed to GGP 22939, which has ary extracellular site of action). The N-amty1-x- 
&lu&myl prddmg of 4'-aminowadariar. was designed as a possible application of the 
prodrug approach to renal selective drug action. Unfortunately, this prodrug did 
not have a renal %elactive action. The cause hereof appeared to be a lurmbination 
of a high plasma protein binding and a limited transport into the kidney (chapter 
6). These findings are i n p o ~ a n t  for the design of new renal prodmgs. The struc- 
ture-transport relationship of N-acetyBr-glutamyl prodmgs will have to be inves- 
tigated in order to be more able to predict the selectivity of these prodrugs. 
In chapter 7, the use of kidney slices as a melthod to assess the reml accumulation 
of the prodrugs is evaluated. These experiments provide additional proof of the 
existmce of a carrier system for N-acetyl-y-glutamyl compounds. Inmbatiom \Kith 
kidney slices are also suited for the determination of intracellular conversion of the 
prodrug and of the ability of the slices ao retain the active drug. Part 2 of this thesis 
is concluded by a discussion on the importance of some pharmacokinetic 
parameters om the renal selectivity by carrier-transported prodrugs, Ht is s h o w  that 
it isvery important to control the plasma concentration of the proidrug at a relatively 
low Bevel, especially if the same carrier system is also present in non-target tissue. 
The possibilities and limitations of the prodrug approach to site-specific drug 
delivery are discussed in chapter 8. Emphasis is laid on the possibility to achieve 
site-specificity "Erough carrier-rnediated transport for (future) drugs with an in- 
tracellular site of action; several tissues are reviewed with respect to their transport 
capabilities. Findly, some possible applications for kidney-selective prodrugs are 
given. 


